risedronic acid has been researched along with Bone Diseases in 4 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Bone Diseases: Diseases of BONES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, JS | 1 |
| Almeida Paz, FA | 1 |
| Braga, SS | 1 |
| Azari, G | 1 |
| Aghayan, S | 1 |
| Seyedjafari, E | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Takahashi, M | 1 |
| Saha, PK | 1 |
| Wehrli, FW | 1 |
1 review available for risedronic acid and Bone Diseases
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compo | 2021 |
3 other studies available for risedronic acid and Bone Diseases
| Article | Year |
|---|---|
Sustained Release of Risedronate from PLGA Microparticles Embedded in Alginate Hydrogel for Treatment of Bony Lesions
Topics: Alginates; Bone Diseases; Cell Line; Delayed-Action Preparations; Hydrogels; Microspheres; Polylacti | 2022 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy.
Topics: Animals; Bone Density; Bone Diseases; Dexamethasone; Etidronic Acid; Glucocorticoids; Magnetic Reson | 2006 |